Introduction
Adeno-associated viruses (AAVs) are small 4.7 kb near single-stranded (ss) DNA Dependoviruses that belong to the Parvoviridae family. Recombinant AAV have gained attention as efficacious and safe gene transfer vehicles over the last 10 years. The recombinant AAV genome consists of two inverted terminal repeats (ITR) of 145 bp each framing the expression cassette. AAV vectors package and deliver an inactive ssDNA genome that is converted into an active double-stranded DNA (dsDNA) in the nucleus. Except for the first generation of vectors, rAAV are devoid of all viral genes, namely the rep and the cap genes that encode respectively the nonstructural Rep proteins involved in the replication of the viral genome, and the Cap proteins, which constitute the viral capsid. 1 Eleven strains of AAV have been identified so far, in addition to more than a hundred sequences corresponding to novel clades of AAV. 2 Gene transfer vectors have been derived from AAV1 to 9, using a pseudotyping strategy, which consists of a recombinant genome framed by the ITR of AAV serotype 2 and a capsid of a different serotype. 1 An impressive amount of effort has been put into viral particle engineering, aimed at modifying the tropism by capsid manipulation, through either switching the capsid (pseudotyping) or designing hybrid particles (mosaic or chimeric capsids). 3 Most of these rAAV have shown capabilities for gene transfer in various organs such as muscle, central and peripheral nervous system, lung, liver, and in conditions such as cancer. 4 In addition to capsid modification, it is desirable to control the fate of the recombinant genome as well as the site, time, level and duration of gene expression. This is constrained by the limited packaging capacity of rAAV, which can barely reach 5 kb. Thus, the choice of the genetic regulatory elements, which may allow for modulation of gene expression is of crucial importance. In this article, we review the main features of expression cassettes, and the various strategies allowed in the context of rAAV.
Choice of the promoter: constitutive, tissue-specific or regulatable Selection of the appropriate transgene promoter is an important issue in determining both the level of expression, and tissue-specificity of rAAV-mediated gene transfer. Constitutive promoters such as the viral cytomegalovirus (CMV) or the hybrid CMV-chicken b-actin (CAG also named CB or CBA) promoters are claimed to be powerful promoters and are frequently used as ubiquitous ones. The CMV enhancer/promoter (573 nucleotides) drives a high level of transgene expression in many different types of cells and tissues. A shortened version of the CMV promoter (with a deletion of nucleotides from À573 to À173) has been recently used to express the CFTR gene with a similar activity compared to the full-length promoter. 5 The CMV promoter is subject to transcriptional silencing in some tissues such as the liver. 6 The CAG (1.2-1.5 kb) promoter is as active as CMV, is not submitted to silencing and is active in various tissues including liver 7 and lung. 8 The natural endogenous promoter of a therapeutic gene offers the possibility of directing expression in the relevant cellular targets at the appropriate level and time. Tissue-specific promoters have been used in a number of settings. In the central nervous system, the neuronspecific enolase (NSE) promoter has been shown to drive stable and high gene expression in the context of a rAAV. 9 In skeletal muscle, tissue specificity is achieved with the synthetic C5-12 promoter consisting of a combination of several myogenic regulatory elements (TEF-1, MEF-1, MEF-2 and TEF-1), 10 the creatine kinase (MCK) promoter 11 or the desmin promoter. 12 The transthyretin (TTR) promoter has been successfully introduced into rAAV to drive specific expression in the liver, and exclusively in the hepatocytes. 13 However, a general feature of these tissue-specific promoters is the low-level of expression achieved compared with their viral counterparts (CMV and CAG).
In some clinical conditions, constitutive expression of the therapeutic protein may be deleterious. Thus, regulatory systems are required temporally and quantitatively to control in vivo the levels of the vector-encoded protein. The regulatory system based on the use of small molecules, such as tetracycline or doxycycline, is the most widely used and represents a versatile system for gene therapy applications. 14, 15 However, leaking activity of the Tet regulatory system (tet-on and tet-off) has been shown to occur. It has been hypothesized to be due to the proximity of either the enhancer/promoter present within AAV ITR or the promoter driving the expression of the tet regulator. Such interference has been reduced by designing a single rAAV encoding an autoregulatory cassette based on two promoters either in opposite or direct orientation. 16, 17 Another strategy using a bidirectional promoter, located in the center of the rAAV genome, 16, 18 has also shown reduction of the leaking activity associated to a high level of induction ( Figure  1) . 18 The rapamycin system has also been described in rAAV for artificial regulation of the transgene in the brain, 19 eye 20 and muscle. 21 Due to the size limitation of the cloned sequences in rAAV, these regulatory systems are split into two separate vectors, one for the delivery of the transgene and one for the delivery of the transactivator-encoding gene. However, the question remains whether the inducer drugs will be appropriate for clinical application.
Finally, the ITRs contain enhancer and transcriptional elements and have been used as an intrinsic weak promoter to drive expression of large genes such as the cystic fibrosis transmembrane conductance regulator (CFTR). Clinical trials have led to variable results suggesting however that conventional promoters should be incorporated to overcome the low mRNA level observed in the CF patients.
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Design of new rAAVs by using the serotype 5 ITR can enhance gene transfer
The ITRs flanking the AAV genome constitute the only viral sequences required in cis for DNA replication and encapsidation. The ITRs of all but one of the AAV serotypes described (excluding the clades) are approximately 90% identical. In contrast, the ITR of AAV5 is only 60% similar to those of the other serotypes, suggesting potential differences in DNA cleavage specificity and nuclear factors involved in viral replication. Standard rAAVs are based on a recombinant genome framed by the ITR of AAV2. A comparison of rAAV5 based on either the AAV2 ITR (pseudotyping) or the AAV5 ITR has been evaluated in mouse skeletal muscle. 25 This study showed that LacZ expression was higher with rAAV5/5 than with rAAV2/2 and rAAV2/5. Similarly, we generated rAAV2/5 and rAAV5/5 encoding the reporter mSEAP protein, a modified secreted form of the murine alkaline phosphatase (Le Bec et al., unpublished data). Following in vivo gene transfer to mouse skeletal muscle, we observed an increase in expression of about two-to three-fold with rAAV5/5 in comparison to rAAV2/5. Furthermore, histological analysis shows that mSEAP expression was distributed in a larger number of myofibers with rAAV5/5 (75%) than with rAAV2/5 (50%). However, this difference in efficiency between ITRs of different origins does not seem to occur in the liver. 26 This suggests that rAAVmediated gene expression can be improved by the use of the AAV5 ITR rather than those of AAV2 in some circumstances and deserves to be evaluated in each tissue of interest. The internal ribosome entry site (IRES) allows translation of two or more genes from one mRNA transcript. Simultaneous expression of several proteins may be relevant for the treatment of infectious disease (HIV) or complex disorders (cancer). Viral IRES (encephalomyocarditis virus, foot and mouth disease virus, hepatitis C virus) and eukaryotic cellular IRES (fibroblast growth factor, c-myc) have been characterized, ranging in size from 150 to 600 nucleotides (available at http://ifr31w3. toulouse.inserm.fr/IRESdatabase/), but the tissue and vector dependency of IRES functions are not well known. 27 The most commonly used is the viral IRES from the encephalomyocarditis virus (EMCV), which is approximately 450 nucleotides long. AAV vectors carrying a bicistronic cassette incorporating an IRES have been described and are mostly used for the co-expression of a therapeutic and a reporter gene in order to evaluate the level of transduction ( Figure 1) . 28, 29 IRES could potentially be used for ex vivo transfer of cytoprotective genes (interleukin-4, heme oxygenase) into pancreatic islets for the treatment of type I diabetes. 30 At this time, no clinical conditions are under evaluation using this technology.
Alternative to IRES elements, 'the self-cleaving' 2A peptide allows generation of an efficient bicistronic AAV vector. Using this approach, a bicistronic AAV cassette was engineered to produce a functional antibody in mice. 31, 32 In addition, the small size of the 2A sequence (69 bp) is particularly attractive in AAV vectors in comparison to the larger IRES.
Incorporation of post-transcriptional regulatory elements can increase rAAV vector expression
Incorporation of the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) into the 3 0 -untranslated region of a gene within rAAV enhances transgene expression by increasing the level of mRNA 18 The transactivator (rtTA) is expressed under the control of the CMV promoter. It binds the tetracycline responsive element (TRE) only upon tetracycline (or doxycycline) addition and stimulates the expression of the transgene. The Tet promoter is composed of the tetracycline response element and the CMV minimal promoter. 15 (c) The bicistronic rAAV vector expresses two genes encoded by the same mRNA under the control of a promoter. Capped mRNA initiates the translation of the first gene, while the second gene is translated from the IRES.
rAAV cassette C Le Bec and AM Douar and the efficiency of translation. Increased expression with the WPRE element in the context of rAAV was achieved in the lung with the CAG promoter, 24 as well as with the CMV promoter after in utero injection. 33 However, despite its beneficial effect on gene expression, WPRE is rather large (600 bp) and can therefore only be used in rAAV cassette where the other genetic elements are small.
Splicing is an important factor that can greatly increase the levels of cytoplasmic mRNA. Addition of a generic intron may be valuable to stimulate gene expression if space is available in the rAAV cassette. However, a recent comparative study showed that inclusion of an intron had a relatively small effect on LacZ expression driven by the CMV promoter in A549 cells. 5 Expressing large cDNA with rAAV cassettes by using the trans-splicing system or the minigene strategy
The limited packaging capacity of 4.7 kb of rAAV creates problems for diseases such as cystic fibrosis, Duchenne muscular dystrophy and hemophilia A, which involve the use of large cDNAs. Two strategies have been explored to circumvent this size constraint, namely trans-splicing and minigene approaches.
The packaging capacity of rAAV can be increased by taking advantage of the property of rAAV genomes to form multimers of several units of the vector genome (concatemerization) following nuclear entry, uncoating and complementary strand synthesis. Based on this, the trans-splicing system allows the reconstitution of a functional gene from two vectors encoding the 5 0 and the 3 0 portions of the gene (Figure 2 ). The presence of donor and acceptor splice sites in appropriate locations, allows the production of a complete mRNA. This approach requires efficient co-administration of both AAV vectors in the same cell. Furthermore, concatemerization between these two independent vector genomes leads to the generation of different multimers (circular, head-to-head, tail-to-tail, head-to-tail, etc.), among which only one (head-to-tail) is suitable for restoring full-length expression of the desired protein. The main limiting step in rAAV mediated trans-splicing appears to be essentially at the level of the mRNA accumulation. 34 This approach has been achieved with reporter and therapeutic genes in the eye, 35 and in human CF airway epithelia. 36 However, the efficiency of trans-splicing vectors was very low in these studies. A recent report showed that a rational design of the gene splitting site led to widespread expression and phenotypic improvement in mdx mice. 37 Finally, Yan et al. 38 demonstrated that the ratio of head-to-tail recombination could be made more efficient by using vectors containing hybrid ITRs of serotype 2 and 5. Such hybrid ITR vectors are less 38 A minigene consists of selected deletions within the coding region and removal of the untranslated sequences. Therefore, the encoded protein is necessarily a truncated form of the wild-type protein, but designed in such a way that it retains its main functionality. Such minigenes have been created to fit into rAAV for the CFTR cDNA which is 7.2 kb. 5 It should be noted that the capability of such minigenes to fully restore a complete CFTR activity is unknown yet. However, this size reduction allows space for additional regulatory elements such as a strong viral or chimeric promoter. 24 Similarly, mini-(about 6 kb in length) and microgenes (3.1-4.2 kb in length) have been designed from the dystrophin cDNA (14 kb). The latter fit into AAV vectors, and allow correct expression and location of a shorter form of dystrophin with restoration of muscle contractile property.
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rAAV vectors can efficiently deliver small RNA molecules AAV vectors have also been used for the delivery of small RNAs as potential therapeutic agents for the inhibition of gene expression or RNA repair. Ribozymes (RNA enzymes) and small interfering RNA (siRNA) are being widely explored for the treatment of dominant negative or infectious diseases or diseases caused by inappropriate gene expression. AAV-vectored ribozymes are now essentially exploited to treat autosomal dominant diseases. Ribozymes bind and cleave a specific mRNA in the absence of other proteins. Stable expression of small ribozymes (o100 nt in length) has been achieved by using AAV viral vectors. The efficiency of ribozymes depends on the optimal design of the expression cassette for endogenous delivery of active ribozymes at high levels. DNA oligonucleotides encoding the ribozyme are mostly cloned downstream of the RNA polymerase II promoter (Pol II) because Pol II efficiently produces active ribozymes. Recently, Yen et al. 39 identified a self-cleaving ribozyme whose function is inhibited by toyocamycin (an analogue of adenosine). By inserting the DNA sequence encoding this ribozyme upstream to the luciferase gene into a rAAV vector, they reported a new technology for modulation of rAAVmediated gene expression in living animals.
siRNA has quickly emerged as a powerful tool for genetic analysis in mammalian cells, and several groups have developed plasmid-and viral-based vectors that express short hairpin RNA (shRNA), which mimics siRNA. In general, rAAV vectors encoding siRNA contain a RNA polymerase III promoter (U6, H1 or 7SK) with a T5 terminator sequence, as well as stuffer DNA, to optimize size for genome packaging. Recently, the first study of rAAV-mediated shRNA expression 40 showed efficient downregulation of gene expression in mammalian cells. Inhibition of the function of NF-kB, one of the pro-inflammatory transcription factors, was successfully achieved in a cellular model with rAAV coding for a siRNA against p65. 41 An attenuation of dengue virus infection in human dendritic cells has also been shown using a rAAV-siRNA vector. 42 These results are encouraging for the application of rAAV-mediated siRNA delivery in a clinical setting for the treatment of infectious diseases. Because the total size of an entire shRNA expression cassette, including the Pol III promoter, is only 300 bp, introduction of a second cassette expressing a fluorescent reporter protein provides additional possibilities, such as the quantification of transduced cells. 43, 44 Finally, Goyenvalle et al. 45 recently generated a rAAV encoding an antisense oligonucleotide to skip a nonsense mutation in exon 23 of the dystrophin mRNA in the mdx mouse model. The antisense sequences were combined with a small nuclear RNA, an essential sequence motif for RNA processing, to facilitate their inclusion into the RNA machinery. The authors showed that dystrophic muscle can be rescued after intra-arterial injection of this rAAV.
To date, the siRNA technology provides a precise and a powerful means of downregulating genes at the RNA level. The majority of gene therapy protocols have been using a single therapeutic gene. For simultaneous targeting of different genes from a single rAAV cassette, it may be possible to clone several shRNA expression cassettes driven by different RNA polymerase III promoters thus avoiding potential recombinations and deletions. At this time, combinatorial siRNA has been established in cultured cells using a nonviral vector system. 46 Double-stranded AAV allow bypassing the rate-limiting conversion step of ssAAV It is well documented that the conversion process, which requires host-cell DNA synthesis machinery, is one of the major limiting steps for the efficiency of rAAV. Furthermore if the AAV genome is half wild-type size, viral particule can package either two copies of a singlestranded AAV genome or one double stranded AAV genome. Thus self-complementary (scAAV) also called double-stranded (ds) AAV vectors have been developed to bypass the rate-limiting step of second strand synthesis (Figure 3) . Two groups have shown that deletion of the D-sequence or mutation of the terminal resolution site of one ITR yields high percentages of scAAV vector. 47, 48 With these modified vectors, gene expression occurs more rapidly and is greater than with ssAAV vectors in mouse liver, brain and muscle. [47] [48] [49] However, the counterpart to this increased efficiency is an even more reduced cloning capacity of 2.3 kb. Thus, small therapeutic agents such as siRNA and ribozymes are ideal to be inserted into a scAAV cassette and Zhong et al. 13 have demonstrated that ribozyme delivery is more efficient with a scAAV vector compared to the standard ssAAV in liver cells and in a mouse model. A recent study with a scAAV vector bearing a siRNA expression cassette showed efficient suppression of MDR1 gene expression in breast cancer cells. 50 This approach may make some tissues, which were initially viewed as non-or poorly transducible by rAAV more eligible for gene therapy.
A better understanding of the mechanisms responsible for rAAV maintenance and their integration capability is needed
Most in vivo studies of rAAV mediated gene transfer have concluded that the vectors are maintained in rAAV cassette C Le Bec and AM Douar transduced cells as extrachromosomal episomes, but also to a lesser extent as integrated forms. Although initially thought to be a marginal phenomenon, random integration of rAAV occurs into the host genome, although at a very low frequency. In addition, the frequency of integration may vary between tissues, probably related to their proliferative status. This question clearly raises concerns; even a rate of 0.05 integrated copies per cell, as observed in mouse liver, would lead to billions of mutated cells in a human liver. A detailed study addressed this question in tyrosinemia type I mice, 51 where integrated proviruses were found in liver cells of injected animals. These authors described a trend for integration of rAAV near gene regulatory sequences. In muscle which is a highly postmitotic tissue, a similar study failed to find integrated forms of rAAV. 52 It is thought that integration occurs via the nonhomologous end-joining pathway of existing double-strand breaks in the cell and that rAAV integration is a consequence of these existing DNA breaks rather than their cause. 53 A recent large-scale analysis of this mechanism in normal human cells in vitro showed a preference for rAAV integration into CpG islands. 54 These studies suggest that of biopsies from AAV-treated patients should be examined for the integrative status of rAAV DNA. 55 Making site-specific integrative rAAV: Rep-mediated integration It is a tempting possibility to make rAAV capable of sitespecific integration. It was shown that wild-type AAV2 integrates in a site-specific manner and without known clinical adverse effect into a 4 kb region of human chromosome 19, named AAVS1. Both the ITR of AAV2 and the large products of the rep gene, the Rep78 and Rep68 proteins, mediate this phenomenon. Although rAAV are devoid of viral genes, various approaches aiming at providing the necessary Rep function along with the rAAV have been envisioned. The main advantage of this AAVS1-directed integration system lies in the theoretical reduction of random integration, with its possible adverse insertional mutagenesis. Several preliminary attempts have relied on different systems ranging from plasmid transfection to viral infection by multiple AAVs (one being the recombinant and one bearing the rep gene) or of hybrid viral systems based on chimeric Ad/AAV vector. These approaches are still in their infancy and have been essentially assessed in vitro 56, 57 or in a AAVS1 transgenic mouse model. 58 However, if such a specific integrative system is to be further developed for human application, one should consider the following safety and regulatory Figure 3 The conventional ssAAV vector (4.7 kb) consists of two wild-type ITR framing the expression cassette. The dsAAV vector contains a deletion in the D-sequence or a mutation in the terminal resolution site of one ITR, while the second ITR is intact, leading to a ds recombinant viral genome limited to half the size (about 2.3 kb) of a ssDNA viral vector genome. Viral genome conversion from a single-to a double-stranded genome by nuclear factors is a major limiting step in the efficiency of ssAAV vector. No conversion of ss-to dsDNA is required for the scAAV vector in the nucleus.
rAAV cassette C Le Bec and AM Douar constraints. First, the Rep proteins should be supplied only temporarily, to allow only the integration of the rAAV but not a later excision/rescue event from the integrated provirus. Second, a low level of Rep would presumably be preferable, first to allow the integration pathway rather than the replication pathway to be utilized, but also because Rep proteins are cytotoxic at high level. Finally, AAVS1 is closely linked to the slow skeletal troponin T gene. 55 Although natural integration seems to have no adverse effect in humans, integration of rAAV close to this gene needs to be shown to be innocuous. Provided that these questions are addressed, this system represents an interesting alternative to other integrative vectors such as oncoretroviruses and lentiviruses for additive gene therapy.
Gene correction is becoming a realistic alternative thanks to rAAV
Recently, it was shown that rAAV could be engineered for use in gene correction. This approach provides a considerable advantage over the classical additive gene therapy. It allows precise gene modification at the exact chromosomal location of the gene of interest, thereby taking advantage of endogenous gene regulation. The principle of rAAV-mediated gene targeting has been validated in vitro, allowing the repair of a defective gene through a single base substitution strategy, with high efficiency. 59 Gene targeting efficiency increases as the length of the homologous sequence between vector and target DNA increases, and it is thought that only the ss incoming genome is involved in the phenomenon. 59 Various types of mutations have been introduced by gene targeting, including bp substitutions, small deletions and insertions (o25 bp) and large deletions and insertions (4300 bp) and combinations of insertion/ deletion. 60 Finally, it seems that double-strand breaks present in the host genome play an important role in this biological process. 61 A recent application of this highly innovative approach has allowed the correction, by genetargeted disruption, of a dominant-negative mutant of the COL1A1 gene in mesenchymal stem cells. 62 Although limited to cell culture in vitro, this technique holds promise for clinical applications in combination to cell therapy. The main challenge for single (or few) base pair gene modification is the improvement of gene targeting frequencies, which is about 10 À6 with classical DNA electroporation or transfection approaches. The main therapeutic perspective at present is limited to ex vivo gene targeting to treat dominant negative diseases. Further in vivo therapeutic applications are still a theoretical perspective, requiring both an improvement of the efficiency in such a context, and a better understanding of the molecular basis governing this process.
Conclusion
Recombinant AAV represent one of the most promising vector systems for gene therapy approaches, combining both a high safety profile and long-term and sustained efficacy. While the initial and limited panel of cell types and tissues that could be efficiently targeted by the first AAV2 based vectors has been extended in the last years due to the development of new recombinant serotypes of AAV vectors, another strategy to improve gene transfer has been made through a rational design of the vector genome. Precise gene correction is now in sight, and the strategies to overcome the second main block of gene transfer following cell penetration, namely the conversion to an active double-stranded genome, is being overcome by the use of alternative techniques such as scAAV. Trans-splicing in disease models is also likely to become a good alternative to mini-or microgene strategy, which remain unsatisfying solution. Moreover, we should see in the future more diseases becoming eligible for rAAV-mediated gene therapy due to the possibility of expressing large cDNA with this technique. Finally, it is likely that combinations of the various approaches discussed here will be developed and evaluated in the next few years. Tailor-made AAV vectors will emerge as a rational strategy for a given disease, depending on its pattern of expression and the size of the therapeutic DNA.
